Is Aloracetam a true racetam?

Despite the name, not structurally: it lacks the pyrrolidone ring that defines the classic racetams. It is classed as a nootropic and a racetam-related compound.

Is there human evidence for its effects?

Essentially none. Aventis studied it for Alzheimer's disease, but it was never marketed and published human clinical evidence is essentially absent.

Its safety is unknown. There are no human clinical safety data, so any use is experimental; this entry is provided for reference only.

EmergingResearch compoundReference only

Aloracetam

Name: Aloracetam
Creator: MolekulaX

Obscure experimental racetam-related compound that Aventis studied for Alzheimer's; virtually no human data.

NootropicRacetamRacetamAcetylcholineAcetylcholineAMPA

Pharmacology

ClassRacetam · Acetylcholine

Primary targetProposed acetylcholine enhancement (unconfirmed)

Targets2 receptor targets

Half-lifeN/A

OnsetN/A

EvidenceReference only

Affected systemsAcetylcholineAMPA

Contents

WHAT IS ALORACETAM?

Detailed overview

Aloracetam is an obscure, experimental nootropic that Aventis investigated for the treatment of Alzheimer's disease, but it was never marketed and development was discontinued. Despite the name it is not a classic racetam structurally: it lacks the pyrrolidone ring that defines the family. Its mechanism of action is essentially uncharacterized in the public literature; beyond a proposed but unconfirmed cholinergic action there is little reliable data. Published human clinical evidence is essentially absent, so this entry serves as reference only.

Mechanism

Uncharacterized (proposed cholinergic)

Half-life

N/A

Onset

N/A

Legal status

Unapproved medicine; unscheduled in the US

Receptor profile

Acetylcholine systemWeak
AMPA receptorsWeak

Safety

Side effects, stop signs, contraindications

Side effects · 3

With virtually no human data, the side-effect profile is unknown; racetam-like effects such as headache are plausible but unconfirmed
Theoretical choline-depletion headache, as with other racetams; a choline source may help in principle
Unknown long-term safety: never marketed and development was discontinued

Contraindications · 3

Pregnancy and breastfeeding: no safety data, should be avoided
Not a medicine: human clinical trials have not established its safety, any use is experimental
Unknown drug interactions: the mechanism is uncharacterized, so co-administration risk cannot be estimated

Related Nootropics

Same therapeutic category

FAQ

Obscure experimental racetam-related compound that Aventis studied for Alzheimer's; virtually no human data.

Have a question about Aloracetam?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeNootropic

FormulaC11H16N2O2

UpdatedJuly 9, 2026

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA

Updated: July 9, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.